{"id":3255,"date":"2014-11-26T16:06:54","date_gmt":"2014-11-26T14:06:54","guid":{"rendered":"http:\/\/pharmakonpress.gr\/?p=3255"},"modified":"2023-12-17T21:05:26","modified_gmt":"2023-12-17T19:05:26","slug":"%cf%84%cf%8c%ce%bc%ce%bf%cf%82-19-2005-%cf%84%ce%b5%cf%8d%cf%87%ce%bf%cf%82-1-%ce%ac%cf%81%ce%b8%cf%81%ce%bf-7-%ce%b5%cf%80%ce%b9%ce%b8%ce%b5%cf%8e%cf%81%ce%b7%cf%83%ce%b7-%ce%ba%ce%bb%ce%b9","status":"publish","type":"post","link":"https:\/\/pharmakonpress.gr\/?p=3255&lang=en","title":{"rendered":"\u03a4\u03cc\u03bc\u03bf\u03c2 19 (2005) – \u03a4\u03b5\u03cd\u03c7\u03bf\u03c2 1 – \u0386\u03c1\u03b8\u03c1\u03bf 7 – \u0395\u03c0\u03b9\u03b8\u03b5\u03ce\u03c1\u03b7\u03c3\u03b7 \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ae\u03c2 \u03a6\u03b1\u03c1\u03bc\u03b1\u03ba\u03bf\u03bb\u03bf\u03b3\u03af\u03b1\u03c2 \u03ba\u03b1\u03b9 \u03a6\u03b1\u03c1\u03bc\u03b1\u03ba\u03bf\u03ba\u03b9\u03bd\u03b7\u03c4\u03b9\u03ba\u03ae\u03c2-\u0394\u03b9\u03b5\u03b8\u03bd\u03ae\u03c2 \u0388\u03ba\u03b4\u03bf\u03c3\u03b7 – Volume 19 (2005) – Issue 1 – Article 7 – Epitheorese Klinikes Farmakologias \u03ba\u03b1\u03b9 Farmakokinetikes-International Edition"},"content":{"rendered":"

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Title<\/strong><\/td>\nEffect of nicotinamide on C-peptide levels in insulin-dependent diabetes mellitus<\/strong><\/td>\n<\/td>\n<\/tr>\n
Authors<\/strong><\/td>\nMaria Gourni\u00b9, Zoi Roupa\u00b2, Christine Marvaki\u00b9, Alexander Ardavanis\u00b3, Penelope Sotiropoulou<\/strong>\u2074<\/strong>, Panayota Gourni<\/strong>\u2075<\/strong> and Christos Bartsokas6<\/sup><\/strong><\/p>\n

1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nursing Department, Educational Technological Institute of Athens, Athens, Greece<\/strong><\/p>\n

2.\u00a0\u00a0\u00a0\u00a0\u00a0 Educational Technological Institute of Larissa, Greece<\/strong><\/p>\n

3.\u00a0\u00a0\u00a0\u00a0\u00a0 Anticancer Institute Agios Savas, Athens, Greece<\/strong><\/p>\n

4.\u00a0\u00a0\u00a0\u00a0\u00a0 Department of Social Services, Bank of Greece, Athens, Greece<\/strong><\/p>\n

5.\u00a0\u00a0\u00a0\u00a0\u00a0 Pamakaristos Hospital, Athens, Greece<\/strong><\/p>\n

6.\u00a0\u00a0\u00a0\u00a0\u00a0 Nursing Department, University of Athens, Athens, Greece<\/strong><\/td>\n

<\/td>\n<\/tr>\n
Citation<\/strong><\/td>\nGourni, M., Roupa, Z., Marvaki, C., Ardavanis, A., Sotiropoulou, P. et al.: Effect of nicotinamide on C-peptide levels in insulin-dependent diabetes mellitus, Epitheorese Klin. <\/strong>Farmakol. Farmakokinet. 19(1): 37-42 (2005)<\/strong><\/td>\n<\/td>\n<\/tr>\n
Publication Date<\/strong><\/td>\nReceived for publication: 15 January 2005<\/strong><\/p>\n

\u00a0Accepted for publication: 8 February 2005<\/strong><\/td>\n

<\/td>\n<\/tr>\n
Full Text Language<\/strong><\/td>\nEnglish<\/strong><\/td>\n<\/td>\n<\/tr>\n
Order – Buy\u00a0<\/strong><\/td>\n\u0397\u03bb\u03b5\u03ba\u03c4\u03c1\u03bf\u03bd\u03b9\u03ba\u03ae \u039c\u03bf\u03c1\u03c6\u03ae: pdf\u00a0(10 \u20ac)<\/strong>\u00a0–\u00a0Digital Type: pdf (10 \u20ac)\u00a0<\/strong><\/p>\n

pharmakonpress[at]pharmakonpress[.]gr<\/strong><\/td>\n

<\/td>\n<\/tr>\n
Keywords<\/strong><\/td>\nInsulin-dependent diabetes mellitus, Nicotinamide, C-peptide.<\/strong><\/td>\n<\/td>\n<\/tr>\n
Other Terms<\/strong><\/td>\nreview article<\/strong><\/td>\n<\/td>\n<\/tr>\n
Summary<\/strong><\/td>\nThe aim of this study is to assess the effect of nicotinamide to c-peptide levels in children during the first six weeks of insulin-dependent diabetes mellitus (IDDM). Thirty-eight children and adolescents, with recent diagnosis (\u2264 6 weeks) of IDDM were studied. Patients were randomized in two groups. In Group A patients received insulin and placebo, while in group B insulin and nicotinamide. Serum c-peptide levels were measured at 0, 3, 6, 9 and 12 months. The total dose of insulin administered the day preceding each sampling was recorded. Results: there was a significant difference between the various average values of c-peptide levels during the second trimester with p=0.01 for group A and p=0.02 for group B. No statistically significant difference was found between the two groups. Similar findings were observed for insulin-dose. Toxicity was negligible and similar in both groups. In conclusion, the treatment of newly diagnosed IDDM with NA does not significantly affect c- peptide levels for a period of time exceeding 6 months. However, this small-size pilot study should be confirmed by a large randomized study with different design involving NA treatment before clinical IDDM.<\/strong><\/td>\n<\/td>\n<\/tr>\n
References<\/strong><\/td>\n1.\u00a0\u00a0\u00a0 Diabetes Epidemiology Research International Mortality Study Group. Major cross-country differences in risk of dying for people with IDDM. Diabetes Care 14:<\/em> 49-54 (1991)<\/p>\n

2.\u00a0\u00a0\u00a0 Green A., Geal E.A.M., Patterson C.C.: Incidence of childhood-onset insulin-dependent diabetes mellitus: the EURODIAB ACE study. Lancet 339:<\/em> 905-909 (1992)<\/p>\n

3.\u00a0\u00a0\u00a0 Maclaren N., Atkinson M.: Is insulin-dependent diabetes mellitus environmentally induced? N. Engl. J. Med. 327:<\/em> 348-349 (1992)<\/p>\n

4.\u00a0\u00a0\u00a0 Kostraba J.N.: What can epidemiology tell us about the role of infant diet In the etiology of IDDM? Diabetes Care 17:<\/em> 87-91 (1994)<\/p>\n

5.\u00a0\u00a0\u00a0 Tuomilehto J., Rewers M., Reunanen A., et al.: increasing trend in type I (insulin-dependent) diabetes mellitus in childhood in Finland. Diabetologia 34:<\/em> 282-287 (1991)<\/p>\n

6.\u00a0\u00a0\u00a0 Drykoningen C.E., Mulder A.L, Vaandrager G.L., La Porte R.E., Bruining G.L.: The incidence of male childhood type I (insulin-dependent) diabetes mellitus is rising rapidly in the Netherlands. Diabetologia 35:<\/em> 139-142 (1992)<\/p>\n

7.\u00a0\u00a0\u00a0 Barnett A.H., Eff C., Leslie R.D.G., Pyke D.A.: Diabetes in identical twins: a study of 200 pairs. Diabetologia 20:<\/em> 87- 93 (1981)<\/p>\n

8.\u00a0\u00a0\u00a0 La Porte R.E., Cruickshanks K.J.: Incidence and risk factors for insulin-dependent diabetes. In: National Diabetes Data Group. Diabetes in America: diabetes data compiled 1984. Bethesda, Md: Department of Health and Human Services, 1985: III-1-III-12. (NIH publication no.85 – 1468)<\/p>\n

9.\u00a0\u00a0\u00a0 Amiel S.A., Caprio S., Sherwin R.S., Plewe G., Haymond M.W., Tamborlane W.V.: Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J. Clin. Endocrinol. Metab. 72:<\/em> 277-282 (1991)<\/p>\n

10.\u00a0 World Health Organization, Department of Non-Communicable Disease Surveillance. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999<\/p>\n

11.\u00a0 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:<\/em> 1183-1197 (1997)<\/p>\n

12.\u00a0 Eisenbarth G.S.: Type l diabetes mellitus: a chronic auto-immune disease. N. Engl. J. Med. 314:<\/em> 1360-1368 (1989)<\/p>\n

13.\u00a0 Mandrup-Poulsen T., Nerup J.: The auto-immune hypothesis of insulin-dependent diabetes: 1965 to the present. In: Auto-immunity and the Pathogenesis of Diabetes (Ginsberg-Fellner F., McEvoy R.C., eds). Pp. 1-28, Springer-Verlag, New York, 1990<\/p>\n

14.\u00a0 Rossini A.A., Greiner D.L., Friedman H.P., Mordes J.P.: Immunopathogenesis of diabetes mellitus. Diabetes Rev. 1:<\/em> 43-75 (1993)<\/p>\n

15.\u00a0 Lo S.S.S., Tun R.Y.M., Leslie R.D.G.: Non-genetic factors causing type I diabetes. Diabetic Med. 8: <\/em>609-618 (1991)<\/p>\n

16.\u00a0 Nerup J.: Etiology and pathogenesis of insulin-dependent diabetes mellitus: present views and future developments. In: Etiology and Pathogenesis of Insulin-dependent Diabetes Mellitus (Martin J.M., Ehrlich R.M., Holland F.J., eds). Pp. 275-288, Raven Press, New York, 1981<\/p>\n

17.\u00a0 Nerup J., Mandrup-Poulsen T., Hokfelt B.: Genes and gene products in the development of diabetes mellitus. Basic and clinical aspects. Experta Medica, International Congress Series 866, Elsevier, Amsterdam, 1989<\/p>\n

18.\u00a0 Mandrup-Poulsen T., Helqvist S., Wogensen L.D., Pociot F., Johannesen J., Nerup J.: Cytocines and free radicals as effector molecules in the destruction of the pancreatic b-cells. Human Diabetes. II. Environmental and Auto-immune Etiology of b-Cell Destruction, Current topics in Microbiology and Immunology (Baekkeskov S., Hansen B., eds). Pp. 163-193, Springer Verlag, Heidelberg, 1990<\/p>\n

19.\u00a0 Cepts W.: Pathology and anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14:<\/em> 619-633 (1965)<\/p>\n

20.\u00a0 Lipes M.A., Rosenzweig A., Tan K.N., Tanigawa G., Ladd D., Seidman J.G., Eisenbarth G.S.: Progression to diabetes in nonodese diabetic (NOD) mice with transgenic T cell receptors. Science 259:<\/em> 1165-1169 (1993)<\/p>\n

21.\u00a0 Hutchings P., Rosen H., O’Reilly L., Simpson E., Gordon S., Cooke A.; Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages. Nature 348: <\/em>639-642 (1990)<\/p>\n

22.\u00a0 Bradley B.J., Haskins K., Rosa F.G.L., Lafferty K.: CD 8+ T cells are not required for islet destruction induced by a CD 4+ cell clone. Diabetes 37:<\/em> 1311-1315 (1988)<\/p>\n

23.\u00a0 Maclaren N., Riley W., Skordis N.: Inherited susceptibility to insulin dependent diabetes is associated with HLA-DR I, while DR5 is protective. Auto-immunity 1:<\/em> 197-205 (1988)<\/p>\n

24.\u00a0 Fauslman D., Li H.Y.: Linkage of faulty major histocompatibility complex class I to auto-immune diabetes. Science 254:<\/em> 1756-61 (1991)<\/p>\n

25.\u00a0 Davies J.L., Kawaguchi Y., Bennett S.T.: A genome-wide search for human type I diabetes susceptibility genes. Nature 371:<\/em> 130-136 (1994)<\/p>\n

26.\u00a0 Dalton T.A., Bennen J.C.: Autoimmune disease, and the major histocompatibility complex: therapeutic implications. Am. J. Med 92:<\/em> 183-188 (1992)<\/p>\n

27. Todd J.A., Bain S.C.: A practical approach to identification of susceptibility genes for IDDM. Diabetes 41:<\/em> 1029- 1034(1992)<\/p>\n

28.\u00a0Todd J.A.: Genetic control of auto-immunity in type I diabetes. Immunol. Today 11:<\/em> 122-129 (1990)<\/p>\n

29.\u00a0 Sheehy M.J.: HLA and insulin-dependent diabetes: a protective perspective. Diabetes 41:<\/em> 123-129 (1992)<\/p>\n

30.\u00a0 Raffel U., Vadheim C.M., Klein R.: HLA-DR and the 5′ insulin gene polymorphism in insulin-dependent diabetes. Metabolism 40: 1244-1248 (1991)<\/p>\n

31.\u00a0 Luocasen A.M., Julier C., Beressi J.-P.: Susceptibility to insulin dependent diabetes melitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat. Genet 4:<\/em> 305-319 (1993)<\/p>\n

32.\u00a0 Caillat-Zucman S., Berlin E., Timsit J., Boitard C., Assan R., Bach J.-F.: Protection from insulin-dependent diabetes mellitus is linked to a peptide transporter gene. Eur. J. Immunol. 23:<\/em> 1784-1788 (1993)<\/p>\n

33.\u00a0 Bingley P.J., Bonifacio E., Gale E.A.M.: Can we really predict IDDM? Diabetes 42:<\/em> 213-220 (1993)<\/p>\n

34.\u00a0 Goodman L.S., Gilman A.: The Pharmacological Basis of Therapeutics. Macmillan. Pp. 1554-1556, New York, 1975<\/p>\n

35.\u00a0 Welsh N., Eizirik D.L., Bendtzen K., Sandler S.: Interleukin-1B-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 129:<\/em> 3167-3173 (1991)<\/p>\n

36.\u00a0 Corbett J.A., Tilton R.G., Chang K., Hasan K.S., Ido Y., Wang J.L., Sweetland M.A., Lancaster J.R.,Jr, Williamson J.R., McDaniel M.L.: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:<\/em> 552-566 (1992)<\/p>\n

37.\u00a0 Corbett J.A., McDaniel M.L.: Does nitric oxide mediate auto-immune destruction of a-cells? Possible therapeutic interventions in IDDM. Diabetes 41:<\/em> 897-903 (1992)<\/p>\n

38.\u00a0 Pickup G, Williams G. Textbook of Diabetes. Oxford. England: Blackwell Scientific, 1991.<\/p>\n

39.\u00a0 Foulis A.K., Liddle C.N., Farquharson M.A., Richmond J.A., Weir R.S.: The histopathology of the pancreas in type I (insulin-dependent) diabetes mellitus: a 25 year review of deaths in patients under 20 years of age in the United Kingdom. Diabetelogia 29:<\/em> 267-274 (1986)<\/p>\n

40.\u00a0 Rossini A.A., Like A.A., Chick W.L., Appel M.C., Cahill G.F.,Jr.: Studies of streptozotocin-induced insulitis and diabetes. Proc. Nat. Acad. Sci. USA 74:<\/em> 2485-2489 (1977)<\/p>\n

41.\u00a0 Yamada K., Nonaka K., Hanafusa T., Miyazaki A., Toyoshima H., Tarui S.: Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 31:<\/em> 749-753 (1982)<\/p>\n

42.\u00a0 Rossini A.A., Mordes J.P., Gallina D.L, Like A.A.: Hormonal and environmental factors in the pathogenesis of BB rat diabetes. Metabolism 32 (Suppl 1):<\/em> 33-36 (1983)<\/p>\n

43.\u00a0 Mendola G., Casamitjana R., Comis R.: Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 32:<\/em> 160-162(1989)<\/p>\n

44.\u00a0 Elliott R.B., Chase H.P.: Prevention or delay of type I (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34:<\/em> 362-365 (1991)<\/p>\n

45.\u00a0 Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G.F., Gamble D.R: In situ characterization of auto-immune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med 313:<\/em> 353-360 (1985)<\/p>\n

46.\u00a0 Manna R., Migliore A., Martini L.S., Ponte E., Marietti G., Scuderi F., Cristiano G., Ghirlanda G., Gambassi G.: Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br. J. Clin. Pract. 46: <\/em>177-179 (1992)<\/p>\n

47.\u00a0 Dunn J.S., Sheehan H.L., McLetchie N.G.B.: Necrosis of islets of Langerhans produced experimentally. Lancet 1:<\/em> 484 (1943)<\/p>\n

48.\u00a0 Rerup C.C.: Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol. Rev. 22:<\/em> 485-520 (1970)<\/p>\n

49.\u00a0 Dulin W.E., Soret M.G.: Chemically and hormonally induced diabetes. In: The Diabetic Pancreas (Volk B.W., Wellmann K.F., eds). Pp. 425-466, Balliere Tindall, London, 1977<\/p>\n

50.\u00a0 Mordes J.P., Rossini A.A.: Animal models of diabetes. Am. J. Med. 70:<\/em> 353-360 (1981)<\/p>\n

51.\u00a0 Rayfield E.J., Ishimura K.: Environmental Factors and insulin-dependent diabetes mellitus. Diabetes\/Metab. Rev 3:<\/em> 925-957(1987)<\/p>\n

52.\u00a0 Burkart V., Koike T., Brenner H.H., Kolb H.: Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 35:<\/em> 1028-1034 (1992)<\/p>\n

53.\u00a0 Dulin W.E., Wyse B.M.: Studies of the ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes 18:<\/em> 459-466 (1969)<\/p>\n

54.\u00a0 Korsgreen O., Andersson A., Sandler 5: Pretreatment of fetal porcine pancreas in culture with nicotinamide accelerates reversal of diabetes after transplantation to nude mice. Surgery 113:<\/em> 205-214 (1993)<\/p>\n

55.\u00a0 Vague P., Vialettes B., Lassmann-Vague V., Vallo J.J.: Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1:<\/em> 619-620 (1987)<\/p>\n

56.\u00a0 Vague P., Picq R., Lassmann-Vague V., Vialettes B.: Effect of nicotinamide treatment on the residual insulin secretion in type I (insulin-dependent) diabetic patients. Diabetologia 32:<\/em> 316-321 (1989)<\/p>\n

57.\u00a0 Herskowitz R.D., Jackson R.A., Soeldner J.S., Eisenbarth G.S: Pilot trial to prevent type I diabetes: progression to overt IDDM despite oral nicotinamide. J. Autoimmun. 2:<\/em> 733-737(1989)<\/p>\n

58.\u00a0 Papaccio G., Ammendola E.: Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule I structures in non-obese diabetic mouse pancreas. J. Endocrinol. 160:<\/em> 389- 400(1999)<\/p>\n

59.\u00a0 Chakrabarti D., Huang X., Beck J., Henrich J., McFarland N., James R.F.L., Stewart T.A.: Control of islet intercellular adhesion molecule-I expression by interferon-a and hypoxia. Diabetes 45:<\/em> 1336-1343 (1996)<\/p>\n

60.\u00a0 Eizirik D.L., Sandler S., Welsh N., Bendtzen K., Hellerstrom C.: Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combination of cytokines. Auto-immunity 19:<\/em> 193-198(1994)<\/p>\n

61.\u00a0 Nicotinamide in NOD mice – G PAPACCIO and others 399, Journal of Endocrinology (1999) 160, 389-400 Hanison LC, Campbell IL, Allison J & Miller JFAP 1989 MHC molecules and A-cell destruction: immune and non-immune mechanisms. Diabetes 38: <\/em>815-818, 1999<\/p>\n

62.\u00a0 Manetti R., Annunziato F., Tomasevic L., Gianno V., Parronchi P., Romagnani S., Maggi E.: Polyinosinic acid: polycytidylic acid promotes T helper type I-specific immune responses by stimulating macrophage production of interferon alpha and IL-12. Eur. J. Immunol. 25:<\/em> 2656-2660 (1995)<\/p>\n

63.\u00a0 Nicoletti F., Zaccone P., Di Marco R., Magro G., Grasso S., Stivala F., Caroli G., Mghini L., Meroni P.L, Garotta G.: Paradoxical anti-diabetogenic effect on a-interferon in DP-BB rats. Diabetes 47:<\/em> 32-38 (1998)<\/p>\n

64.\u00a0 Lewis C.M., Canafax D.M., Sprafka J.M., Barbosa J.J.: Double-blind randomized trial of nicotinamide on early-onset diabetes. Diabetes Care 15:<\/em> 121-123 (1992)<\/p>\n

65.\u00a0 Vidal J., Fernande M., Sesmil G., Aguilera E.: Effects of Nicotinamide and Intravenous Insulin Therapy in Newly Diagnosed Type 1 Diabetes. Diabetes Care 23:<\/em> 360-364 (2000)<\/p>\n

66.\u00a0 Schnell O., Eisfelder B., Standi E., Ziegler A.G.: High dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 46:<\/em> 1607- 1611 (1997)<\/p>\n

67.\u00a0 Visalli N., Cacalli M., Signore A., Baroni M.: A multi centered randomized trial of two different doses of nicotinamide in patients with recent onset Type 1 diabetes. Diabetes 15:3<\/em> 181-185(1999<\/td>\n

<\/td>\n<\/tr>\n
Relative Papers<\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Online ISSN 1011-6575<\/strong><\/p>\n

\u0386\u03c1\u03b8\u03c1\u03b1 \u0394\u03b7\u03bc\u03bf\u03c3\u03b9\u03b5\u03c5\u03bc\u03ad\u03bd\u03b1 \u03c3\u03b5 \u03b1\u03c5\u03c4\u03cc \u03c4\u03bf \u03a0\u03b5\u03c1\u03b9\u03bf\u03b4\u03b9\u03ba\u03cc \u039a\u03b1\u03c4\u03b1\u03c7\u03c9\u03c1\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03c3\u03c4\u03b1:<\/p>\n